AIM Stock — AIM ImmunoTech Inc.: Cash, EV, Pipeline

Share price

$0.21

Market cap

$7.4M

Cash

$10.0M

Enterprise value

$1.0M

Balance sheet

Cash	$10.0M
Debt	$3.6M
Net cash	$6.4M
Enterprise value	$1.0M
Basic shares	29.0M shares
Fully diluted shares	34.8M shares
Fully diluted market cap	$7.3M
Cash per share	$0.34

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading AIM daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Sep 12 - Oct 24	Paclitaxel	Phase 2	Ovarian Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Ampligen

Phase 2 · Active Modality: double-stranded RNA (dsRNA), TLR3 agonist

Aliases rintatolimod

Target TLR3

Partnerships Filaxis (commercial partner, Latin America — Ampligen in Argentina); AstraZeneca Imfinzi (durvalumab) used in combination in investigator-initiated DURIPANC study at Erasmus MC (no agreement terms disclosed)

Indications

Metastatic pancreatic cancer (with Imfinzi/durvalumab, post-FOLFIRINOX) (Phase 2)
Locally advanced pancreatic cancer (AMP-270) (Phase 2)
ME/CFS and post-COVID fatigue (Phase 2)
Advanced recurrent ovarian cancer (Phase 2)
Influenza vaccine adjuvant (with FluMist; includes avian influenza) (Stage not disclosed)

Catalysts

— later in 2026

Status note Company's stated focus is Ampligen in late-stage pancreatic cancer following its pancreatic-cancer Early Access Program; anticipated Phase 3 design work under Mar 2026 agreement with PPD clinical research (Thermo Fisher), trial not yet initiated. AMP-518 (post-COVID conditions) completed 2023; close-out finished 2025; final results posted to ClinicalTrials.gov Jan 2025. Phase 1 portion of DURIPANC led to ongoing Phase 2 portion; all subjects enrolled and dosed as of Jun 30, 2026.

Alferon N Injection

Approved · Active

Aliases Interferon alfa

Target Interferon alfa receptor (IFNAR)

Indications

Condylomata acuminata (genital warts) (Approved)

Status note Approved commercial product; commercial sales halted due to lack of finished goods inventory per this filing.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT03899987	Phase 2	Active, not recruiting	Collaborator	Roswell Park Cancer Institute	—	Prostate Adenocarcinoma; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8	—
NCT07634094	Phase 2	Not yet recruiting	Collaborator	Kalinski, Pawel, MD, PhD	—	Ovarian Cancer	—
NCT03734692	Phase 2	Active, not recruiting	Collaborator	Robert Edwards	MRK	Ovarian Cancer Recurrent	—
NCT05927142	Phase 2	Recruiting	Collaborator	Joachim Aerts, MD PhD	AZN	Metastatic Pancreatic Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 4 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Roswell Park Cancer Institute on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

AIM — AIM ImmunoTech Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Active clinical trials